Skip to main navigation menu Skip to main content Skip to site footer


Vol. 150 No. 1920 (2020)

Five reasons why data on compassionate use of remdesivir deserved publication (and are worth reading)

  • Giuseppe Lapadula
Cite this as:
Swiss Med Wkly. 2020;150:w20265


  1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.
  2. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222.
  3. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020;NEJMoa2007016.
  4. Drazen JM. Data Sharing and the Journal. N Engl J Med. 2016;374(19):e24.
  5. Hasan K, et al. COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. J Heart Lung Transplant. 2020. [Epub ahead of print].
  6. Gottlieb MS. Discovering AIDS. Epidemiology. 1998;9(4):365–7.
  7. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;278(7216):1358. doi:.
  8. Riou B, Barriot P, Rimailho A, Baud FJ. Treatment of severe chloroquine poisoning. N Engl J Med. 1988;318(1):1–6.
  9. Morris AH, Wallace CJ, Menlove RL, Clemmer TP, Orme JF, Jr, Weaver LK, et al. Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med. 1994;149(2 Pt 1):295–305.